NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Forecast, Price & News $1.33 +0.03 (+2.31%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.29▼$1.3550-Day Range$0.79▼$1.7552-Week Range$0.76▼$3.00Volume14,921 shsAverage Volume56,487 shsMarket Capitalization$25.90 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Regulus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside576.7% Upside$9.00 Price TargetShort InterestHealthy1.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.53) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector1079th out of 1,980 stocksPharmaceutical Preparations Industry531st out of 978 stocks 3.5 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Regulus Therapeutics has a forecasted upside of 576.7% from its current price of $1.33.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.56% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regulus Therapeutics has recently increased by 26.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 1.1 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Regulus Therapeutics this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.29% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions55.47% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to grow in the coming year, from ($1.53) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regulus Therapeutics (NASDAQ:RGLS) StockRegulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.Read More Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Stock News HeadlinesMay 30, 2023 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Sees Significant Growth in Short InterestMay 25, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.comJune 1, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | americanbankingnews.comHC Wainwright Analysts Cut Earnings Estimates for Regulus Therapeutics Inc. (NASDAQ:RGLS)May 17, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Receives New Coverage from Analysts at StockNews.comMay 16, 2023 | finance.yahoo.comRegulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)May 15, 2023 | msn.comHC Wainwright & Co. Reiterates Regulus Therapeutics (RGLS) Buy RecommendationMay 12, 2023 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent UpdatesJune 1, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 11, 2023 | seekingalpha.comRegulus Therapeutics GAAP EPS of -$0.42 beats by $0.02May 11, 2023 | finance.yahoo.comRegulus Therapeutics Reports First Quarter 2023 Financial Results and Recent UpdatesMay 10, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.comApril 29, 2023 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest UpdateApril 25, 2023 | americanbankingnews.comHC Wainwright Weighs in on Regulus Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:RGLS)April 21, 2023 | msn.comHC Wainwright & Co. Maintains Regulus Therapeutics (RGLS) Buy RecommendationApril 21, 2023 | americanbankingnews.comHC Wainwright Cuts Regulus Therapeutics (NASDAQ:RGLS) Price Target to $9.00April 20, 2023 | americanbankingnews.comFinancial Survey: Regulus Therapeutics (NASDAQ:RGLS) & ASLAN Pharmaceuticals (NASDAQ:ASLN)April 16, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.comApril 13, 2023 | msn.comWhy Regulus Therapeutics Shares Are Trading Higher TodayApril 13, 2023 | finance.yahoo.comRegulus Therapeutics Announces $15 Million Private Placement of EquityApril 12, 2023 | finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 8, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)March 30, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.comMarch 25, 2023 | benzinga.comRegulus Therapeutics Stock (NASDAQ:RGLS), Short Interest ReportMarch 24, 2023 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent UpdatesMarch 23, 2023 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent UpdatesMarch 9, 2023 | benzinga.comRegulus Therapeutics Stock (NASDAQ:RGLS), Guidance and ForecastSee More Headlines RGLS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Company Calendar Last Earnings3/23/2023Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+576.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.02% Return on Assets-60.46% Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92 Sales & Book Value Annual Sales$10.01 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.97Miscellaneous Outstanding Shares19,480,000Free Float17,861,000Market Cap$25.91 million OptionableOptionable Beta1.56 Key ExecutivesJoseph P. HaganPresident, Chief Executive Officer & DirectorCrispina CalsadaChief Financial OfficerClaire S. PadgettSenior Vice President-Clinical OperationsChristopher AkerSecretary, Senior Vice President & General CounselBrian K. CampionVice President-Business DevelopmentKey CompetitorsMolecular TemplatesNASDAQ:MTEMInfinity PharmaceuticalsNASDAQ:INFICatalyst BiosciencesNASDAQ:CBIOBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIOView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 400 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions RGLS Stock - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price forecast for 2023? 3 brokers have issued 1-year target prices for Regulus Therapeutics' shares. Their RGLS share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 576.7% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2023? Regulus Therapeutics' stock was trading at $1.37 at the beginning of 2023. Since then, RGLS stock has decreased by 2.9% and is now trading at $1.33. View the best growth stocks for 2023 here. Are investors shorting Regulus Therapeutics? Regulus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 253,700 shares, an increase of 26.0% from the April 30th total of 201,300 shares. Based on an average daily trading volume, of 67,000 shares, the short-interest ratio is presently 3.8 days. Approximately 1.6% of the shares of the stock are short sold. View Regulus Therapeutics' Short Interest. When is Regulus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RGLS earnings forecast. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. When did Regulus Therapeutics' stock split? Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). What is Regulus Therapeutics' stock symbol? Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS." Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regulus Therapeutics' stock price today? One share of RGLS stock can currently be purchased for approximately $1.33. How much money does Regulus Therapeutics make? Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $25.91 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-28,320,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. How can I contact Regulus Therapeutics? Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com. This page (NASDAQ:RGLS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.